We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Korean Coronary Bifurcation Stenting (COBIS) Registry II

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01642992
Recruitment Status : Completed
First Posted : July 17, 2012
Last Update Posted : January 10, 2013
Information provided by (Responsible Party):
Hyeon-Cheol Gwon, Samsung Medical Center

Brief Summary:

The COBIS II registry is a multi-center, real-world registry of drug-eluting stenting in coronary bifurcation lesions in South Korea. From 18 major coronary intervention centers in Korea, a total of 2,873 patients were enrolled in this database between January 2003 and December 2009.

The aim of the study was to investigate long-term clinical results and predictors of adverse outcomes after percutaneous coronary intervention with drug-eluting stents for coronary bifurcation lesions in South Korea.

Condition or disease
Coronary Bifurcation Lesion

Study Type : Observational
Actual Enrollment : 2873 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Korean Coronary Bifurcation Stenting (COBIS) Registry II
Study Start Date : January 2011
Primary Completion Date : April 2012
Study Completion Date : April 2012

Coronary bifurcation lesion

Primary Outcome Measures :
  1. Incidence of the composite outcomes of cardiac death, target vessel-related myocardial infarction, or target-lesion revascularization [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. Cardiac death [ Time Frame: 3 years ]
  2. Myocardial infarction [ Time Frame: 3 years ]
  3. Target lesion revascularization [ Time Frame: 3 years ]
  4. Stent thrombosis [ Time Frame: 3 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with coronary bifurcation lesion treated with drug-eluting stents

Inclusion Criteria:

  • Age >= 18 years
  • Any type of bifurcation lesion in major epicardial artery
  • Side branch reference diameter >= 2.3 mm and at least stentable with 2.5 mm stent
  • Treated with drug-eluting stent

Exclusion Criteria:

  • Protected left main disease previous CABG for LAD or LCX territory
  • Cardiogenic Shock
  • History of CPR in the same hospitalization

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01642992

Korea, Republic of
Samsung Medical Center
Seoul, Korea, Republic of, 135-710
Sponsors and Collaborators
Hyeon-Cheol Gwon

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Hyeon-Cheol Gwon, Professor, Samsung Medical Center
ClinicalTrials.gov Identifier: NCT01642992     History of Changes
Other Study ID Numbers: 2010-11-060
First Posted: July 17, 2012    Key Record Dates
Last Update Posted: January 10, 2013
Last Verified: January 2013

Keywords provided by Hyeon-Cheol Gwon, Samsung Medical Center:
Coronary bifurcation lesion
Drug-eluting stent